Provenienza dei contatti di primo grado di Lars H. Engelholm
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
ADCendo ApS
ADCendo ApS BiotechnologyHealth Technology ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.
9
| Holding Company | Biotechnology | 9 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Lars H. Engelholm tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
CELGENE | Biotechnology | Corporate Officer/Principal | |
ImClone LLC
ImClone LLC BiotechnologyHealth Technology ImClone LLC develops targeted biologic treatments designed for the medical needs of patients with tumors. The company was founded in 1984 and is headquartered in Bridgewater, NJ. | Biotechnology | Chief Tech/Sci/R&D Officer | |
IMMUNOMEDICS, INC. | Biotechnology | Chief Executive Officer | |
TIGENIX NV | Medical Specialties | Director/Board Member | |
AURA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
HealthCap AB
HealthCap AB Investment ManagersFinance HealthCap AB (HealthCap) is a venture capital subsidiary of Odlander, Fredrikson & Co. AB founded in 1995 by Björn Ingemar Odlander and Peder Fredrikson. The firm is headquartered in Stockholm, Sweden with an additional office in Switzerland. | Investment Managers | Private Equity Investor | |
Copenhagen Business School | College/University | Graduate Degree | |
University of Aarhus | College/University | Doctorate Degree | |
Roche Innovation Center Copenhagen A/S
Roche Innovation Center Copenhagen A/S Pharmaceuticals: MajorHealth Technology Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark. | Pharmaceuticals: Major | Chief Executive Officer | |
Roche Glycart AG
Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland. | Pharmaceuticals: Major | Chief Executive Officer | |
AM-Pharma Holding BV
AM-Pharma Holding BV Pharmaceuticals: MajorHealth Technology AM-Pharma Holding BV operates as a financial holding company with interests in the bio-medical sector. The company was founded by Rudd Brands and is headquartered in Bunnik, Netherlands. | Pharmaceuticals: Major | Director/Board Member | |
Swiss Federal Institute of Technology | College/University | Doctorate Degree | |
Ludwig-Maximilians-Universität München | College/University | Undergraduate Degree | |
Cellerix SA
Cellerix SA Pharmaceuticals: GenericHealth Technology Founded in 2004, Cellerix is a biopharmaceutical company that develops innovative treatments based on cell therapy. Cellerix was founded within the Genetrix Group, group of biotechnology companies specialising in biomedicine. The Genetrix Group began its activities in 2001 at the National Centre for Biotechnology (CNB), which belongs to the Spanish Research Council (CSIC). One of the main objectives of Genetrix is to convert basic research results into therapeutic realities. Cellerix is leading the development of a new generation of medicines using expanded adult stem cells from adipose tissue (eASCs). Development is at a clinically advanced stage and the results from clinical trials in Phase I and II have been very promising. Obtaining these eASCs has big advantages because the process makes use of tissue that is almost always discarded from surgical procedures such as liposuction. eASCs have the capacity to activate physiological repair mechanisms through interaction with affected tissue. This technology represents a revolution in the treatment of some diseases that cannot satisfactorily be cured at present. Cellerix is working actively to adapt this new therapeutic strategy to treat autoimmune diseases such as inflammatory bowel disease. The main goal of the company is to market new tools for treating these diseases, which have a considerable negative impact of the quality of life of the sufferers. Cellerix also researches and develops medicines in other areas such as the development of skin equivalents, which are initially intended for the treatment of hereditary diseases such as epidermolysis bullosa. | Pharmaceuticals: Generic | Chairman | |
Gilde Healthcare Partners BV
Gilde Healthcare Partners BV Investment ManagersFinance Gilde Healthcare Partners BV is a Private Equity/Venture Capital firm, a subsidiary of Gilde Healthcare Holding BV founded in 1999 by Pieter van der Meer and Edwin William de Graaf. Gilde Healthcare Partners BV is headquartered in Utrecht with additional office in Cambridge. | Investment Managers | Private Equity Investor | |
Ysios Capital Partners SGEIC SA
Ysios Capital Partners SGEIC SA Investment ManagersFinance Ysios Capital Partners SGEIC SA (Ysios Capital) is a venture capital firm founded in 2007 by Joël Jean Pierre Jean-Mairet, Julia Salaverría Monfort and Josep Lluís Sanfeliu Benet. The firm is headquartered in San Sabastian, Spain with additional office in Barcelona. | Investment Managers | Founder | |
Sanifit Therapeutics SA
Sanifit Therapeutics SA BiotechnologyHealth Technology Sanifit Therapeutics SA develops pharmaceuticals for calcification disorders. Its pipeline consists of treatments for calcification disorders, such as calciphylaxis and osteoporosis. The company was founded by Felix Grases in 2004 and is headquartered in Palma de Mallorca, Spain. | Biotechnology | Director/Board Member | |
Novo Seeds
Novo Seeds Investment ManagersFinance Novo Seeds (Novo Seeds) is a venture capital operating division of Novo Nordisk Fonden. The firm was established in 2007, and is headquartered in Hellerup, Denmark. | Investment Managers | Private Equity Analyst | |
SwedenBIO Service AB
SwedenBIO Service AB Miscellaneous Commercial ServicesCommercial Services SwedenBIO Service AB is a non-profit company that develops biotechnology, diagnostics, pharmaceuticals, and medical technology. It also offers counseling, education, opinion formation, and investigations. The company was founded in 2002 and is headquartered in Stockholm, Sweden. | Miscellaneous Commercial Services | Director/Board Member | |
Danish Cancer Society
Danish Cancer Society Miscellaneous Commercial ServicesCommercial Services The Danish Cancer Society provides support and resources for those affected by cancer, including patients and their families. The non-profit company is based in Copenhagen, Denmark and has subsidiaries in Denmark. The Danish company offers the latest information on patient involvement in cancer treatment and tools for utilizing patient-reported information. The organization also promotes cancer prevention through screening and works towards reducing the number of cancer cases and improving the quality of life for those who have survived cancer. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Medlumics SL
Medlumics SL Medical SpecialtiesHealth Technology Medlumics SL provides medical imaging diagnostics services. It specializes in optically guided medical devices. The firm’s proprietary integrated optics platform technology combines optical and electrical components in a miniature chip, enabling for the first time complex multi view optical probes of the size of a grain of rice and ultra-portable, hand-held OCT systems that produces real-time images. The company was founded by Eduardo Margallo Balbás and Jose Luis Rubio Guivernau on April 3, 2009 and is headquartered in Tres Cantos, Spain. | Medical Specialties | Director/Board Member | |
iSD Immunotech ApS
iSD Immunotech ApS BiotechnologyHealth Technology iSD Immunotech ApS develops immunoregulatory peptides and proteins. It conducts research and development on immunoregulatory peptides for possible applications and commercialization. The company was founded by Peter Samuel Wulff, Shervin Bahrami, Finn Skou Pedersen, Mogens Ryttergård Duch, Lars Jørgen Østergaard, Martin Tolstrup, and Martin Thygesen on August 9, 2007 and is headquartered in Aarhus, Denmark. | Biotechnology | Director/Board Member | |
Inbiomotion SL
Inbiomotion SL Medical SpecialtiesHealth Technology Inbiomotion SL designs and develops diagnostic assays. It focus on genetic biomarkers, which predict the bone-specific metastases in cancer patients. The firm develops biomarker in breast cancer primary tumors for predicting the bone relapse. The company was founded by in 2010 and is headquartered in Barcelona, Spain. | Medical Specialties | Chairman | |
F-star Alpha Ltd.
F-star Alpha Ltd. BiotechnologyHealth Technology F-star Alpha Ltd. develops novel bispecific antibody products. It focuses on treatment of breast and gastric cancer among a population of HER2-positive patients who do not respond or become resistant to current therapies. The company was founded in October 2013 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer | |
Anterra Capital BV
Anterra Capital BV Investment ManagersFinance Anterra Capital BV (Anterra Capital) is an independent private equity firm founded in 2013. The firm is headquartered in Amsterdam, Netherlands. | Investment Managers | Private Equity Analyst | |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Biotechnology | Director/Board Member | |
SYNACT PHARMA AB | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Ventac Partners A/S
Ventac Partners A/S Miscellaneous Commercial ServicesCommercial Services Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Investment Managers | Private Equity Investor | |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Investment Managers | Private Equity Analyst | |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
F-Star Beta Ltd.
F-Star Beta Ltd. BiotechnologyHealth Technology F-Star Beta Ltd. is a biopharmaceutical company that focused in the development of oncology and immune-oncology products. The company was founded on October 14, 2014 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member | |
CatalYm GmbH
CatalYm GmbH Pharmaceuticals: MajorHealth Technology CatalYm GmbH specializes in catalyzing immunotherapy. The company is headquartered in Munich, Germany. | Pharmaceuticals: Major | Chairman | |
NeoPhore Ltd.
NeoPhore Ltd. Miscellaneous Commercial ServicesCommercial Services NeoPhore Ltd. engages in discovery and development of small molecules inhibitors to treat cancer. The company is headquartered in Kings Cross, London, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Doctrin AB
Doctrin AB Internet Software/ServicesTechnology Services Doctrin AB offers consultancy services within healthcare sector. It offers digital solutions that enable healthcare providers to prioritize, treat, and follow-up with their patients. The company was founded by Per Eriksson, Ashkan Labaf, Magnus Liungman, and Carslo Lorente in 2016 and is headquartered in Stockholm, Sweden. | Internet Software/Services | Director/Board Member | |
DJS Antibodies Ltd.
DJS Antibodies Ltd. BiotechnologyHealth Technology DJS Antibodies Ltd. designs and discovers novel therapeutic monoclonal antibodies against G-protein-coupled receptors. The firm conducts discovery against three targets in the fields of oncology, fibrosis and vascular disease. The company was founded by David Colin Conway Llewellyn and Joseph James Illingworth and is headquartered in Bicester, the United Kingdom. | Biotechnology | Director/Board Member | |
Next Stage Ventures ApS
Next Stage Ventures ApS Miscellaneous Commercial ServicesCommercial Services Next Stage Ventures ApS is a Danish company that focuses on researching and developing biotechnology products. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
ResoTher Pharma AS
ResoTher Pharma AS Pharmaceuticals: MajorHealth Technology ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors. | Pharmaceuticals: Major | Director/Board Member | |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Biotechnology | Director/Board Member | |
AgomAb Therapeutics NV
AgomAb Therapeutics NV Miscellaneous Commercial ServicesCommercial Services AgomAb Therapeutics NV operates as a Belgian biotherapeutics company, developing agonistic antibodies for regeneration of damaged tissues. The company was founded by Paolo Michieli, Manuela Cazzanti, Virginia Morello, Federica Caterina Linty, Michael Potter Saunders, and Hans J. W. de Haard in 2017 and is headquartered in Ghent, Belgium. | Miscellaneous Commercial Services | Chairman | |
Synklino ApS
Synklino ApS Medical/Nursing ServicesHealth Services Synklino ApS is a Danish biotech company that focuses on developing innovative therapies against virus infections. The company's first-in-class drug candidate, Syn002, targets cytomegalovirus infection in transplantation patients and aims to change the current antiviral treatment paradigm. Synklino is owned by renowned Nordic funds and institutional investors, including Eir Ventures, the Danish Growth Fund, and PKA, as well as approximately 70 private shareholders. The company is a spinout from the University of Copenhagen and the Technical University of Denmark and is incubated at the BioInnovation Institute in its prestigious Creation House program. | Medical/Nursing Services | Chairman | |
Ona Therapeutics SL
Ona Therapeutics SL Pharmaceuticals: MajorHealth Technology Ona Therapeutics SL is a biotech company based in Barcelona, Spain that specializes in discovering and developing therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism. The Spanish company's focus is on developing novel therapies against advanced cancer. The company was founded in 2019 by Salvador Aznar Benitah and Valerie Liesbeth Brigitte Vanhooren, with Valerie Liesbeth Brigitte Vanhooren serving as CEO since incorporation. | Pharmaceuticals: Major | Director/Board Member | |
GEMoaB Monoclonals GmbH
GEMoaB Monoclonals GmbH Pharmaceuticals: MajorHealth Technology Part of AvenCell Therapeutics, Inc., GEMoaB Monoclonals GmbH is a German company that manufactures biopharmaceutical products. The company is based in Dresden, Germany. The company was founded in 2014 by Gerhard Ehninger. GEMoaB Monoclonals was acquired by AvenCell Therapeutics, Inc. from Cellex Cell Professionals GmbH on March 30, 2022. | Pharmaceuticals: Major | Chief Executive Officer | |
Rappta Therapeutics Oy
Rappta Therapeutics Oy BiotechnologyHealth Technology Rappta Therapeutics Oy operates as a biopharmaceutical company. It develops anti-cancer drugs activating protein phosphatase 2A. The company was founded by Goutham Narla and Mikko Lauri Sampsa Mannerkoski on March 20, 2019 and is headquartered in Helsinki, Finland. | Biotechnology | Director/Board Member | |
Synox Therapeutics Ltd.
Synox Therapeutics Ltd. BiotechnologyHealth Technology Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland. | Biotechnology | Director/Board Member | |
Medify AB | Chief Executive Officer | ||
F-star Biotechnology Ltd.
F-star Biotechnology Ltd. BiotechnologyHealth Technology F-Star Biotechnology Ltd. is a biopharmaceutical company. It discovers, develops, and manufactures bispecific antibody products. The company is headquartered in Cambridge, the United Kingdom. | Biotechnology | Chief Executive Officer |
Statistiche
Distribuzione geografica
Danimarca | 11 |
Regno Unito | 8 |
Stati Uniti | 7 |
Svezia | 7 |
Spagna | 7 |
Settori
Health Technology | 29 |
Finance | 8 |
Commercial Services | 7 |
Consumer Services | 5 |
Technology Services | 2 |
Posizioni
Director/Board Member | 32 |
Chief Executive Officer | 10 |
Chairman | 7 |
Founder | 6 |
Private Equity Analyst | 5 |
Contatti più connessi
- Borsa valori
- Insiders
- Lars H. Engelholm
- Connessioni Società